Hutchmed (China) Limited

HCM | HKEX

Overview

ISIN(s):: KYG4672N1198 (+1 more)
LEI:: 2138006X34YDQ6OBYE79
Country:: Hong Kong
Address:: LEVEL 18, THE METROPOLIS TOWER, KOWLOON
Website:: https://www.hutch-med.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

No description available.

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

Date	Filing	Language	Size
2025-11-05 08:25	Regulatory News Service Enrollment Complete in SAFFRON Global Phase III	English	29.9 KB
2025-11-03 08:30	Regulatory News Service Updates from R&D Event	English	23.6 KB
2025-10-23 08:00	Regulatory News Service HUTCHMED Presents Data at AACR NCI EORTC	English	20.4 KB
2025-10-21 10:30	Remuneration Information Vesting of awards under Long Term Incentive Plan	English	41.6 KB
2025-10-14 10:30	Board/Management Information Appointment of Independent Non-executive Director	English	20.0 KB
2025-10-13 08:05	Earnings Release Data to be Presented at the 2025 ESMO Congress	English	23.1 KB
2025-10-02 08:00	Regulatory News Service HUTCHMED Highlights Data to be Presented at ESMO	English	32.5 KB
2025-09-30 10:30	Declaration of Voting Results & Voting Rights Announcements Total Voting Rights	English	13.3 KB
2025-08-26 08:00	Board/Management Information Directorate Change	English	17.9 KB
2025-08-20 08:00	Regulatory News Service HUTCHMED Completes Enrollment of Phase III Trial	English	29.1 KB
2025-08-07 13:00	Earnings Release 2025 Interim Results	English	141.5 KB
2025-07-03 10:30	Report Publication Announcement HUTCHMED to Announce 2025 Half-Year Results	English	12.1 KB
2025-06-30 10:30	Declaration of Voting Results & Voting Rights Announcements Total Voting Rights	English	12.4 KB
2025-06-30 10:30	Remuneration Information Blocklisting Six Monthly Return	English	25.1 KB
2025-06-30 10:30	Regulatory News Service China Approval based on Phase III SACHI Trial	English	29.8 KB

Automate Your Workflow. Get a real-time feed of all Hutchmed (China) Limited filings delivered via API.

No data available

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Hutchmed (China) Limited via our API.

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Company	Country	Ticker
AGIOS PHARMACEUTICALS, INC. Pioneering cellular metabolism therapies for rare, genetically defined diseases like anemias.	United States of America	AGIO
AIM ImmunoTech Inc. Develops immuno-therapeutics for cancers, immune disorders, and viral diseases.	United States of America	AIM
AKANDA CORP. Cultivates and distributes pharma-quality medical cannabis for patients in legal markets worldwide.	United States of America	AKAN
Akari Therapeutics Plc A clinical-stage oncology company developing next-gen ADCs for targeted cancer therapy.	United States of America	AKTX
Akebia Therapeutics, Inc. Developing and commercializing novel, FDA-approved therapeutics for kidney disease.	United States of America	AKBA
Akero Therapeutics, Inc. A clinical-stage biotech developing therapies for serious metabolic diseases like MASH.	United States of America	AKRO
Alaunos Therapeutics, Inc. Developing TCR-T cell therapies to treat solid tumors by targeting specific cancer mutations.	United States of America	TCRT
Aldeyra Therapeutics, Inc. Biotech developing therapies for ocular and systemic immune-mediated inflammation.	United States of America	ALDX
Alector, Inc. Pioneers immuno-neurology therapies for neurodegenerative diseases like Alzheimer's.	United States of America	ALEC
Aligos Therapeutics, Inc. Clinical-stage biopharma developing novel oral therapies for liver and viral diseases.	United States of America	ALGS